

Identification and distribution of endoplasmic reticulum iPLA₂

Gilbert R. Kinsey^a, Brian S. Cummings^b, Caroline S. Beckett^c, Geraldine Saavedra^b,
Wenliang Zhang^b, Jane McHowat^c, Rick G. Schnellmann^{a,*}

^a Department of Pharmaceutical Sciences, Medical University of South Carolina, 280 Calhoun, P.O.B. 250140, Charleston, SC 29425, USA

^b Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA

^c Department of Pathology, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO 63104, USA

Received 30 November 2004

Available online 18 December 2004

Abstract

Our laboratory demonstrated that endoplasmic reticulum iPLA₂ (ER-iPLA₂) activity protects renal cells from oxidant-induced cell death and lipid peroxidation. The goals of this study were to determine the PLA₂ isoform(s) responsible for ER-iPLA₂ activity in different species and tissues. ER-iPLA₂ activity was observed in microsomes from rabbit and rat kidney, heart, and brain as well as in human kidney (Caki-1 and HEK293) and glioblastoma (A172) cell lines. Reverse transcriptase-polymerase chain reaction results demonstrated the presence of iPLA₂γ (group VIB PLA₂) message in all tissues tested. Immunoblot analysis and PLA₂ inhibitor studies with methyl arachidonyl fluorophosphonate and enantiomers of bromoenol lactone demonstrated that the ER-iPLA₂ in rabbit kidney and heart and rat kidney is iPLA₂γ. These results demonstrate the expression of ER-iPLA₂γ (group VIB) across species and tissues, and suggest that iPLA₂γ may play critical roles in oxidant-induced cell injury.

© 2004 Elsevier Inc. All rights reserved.

Keywords: iPLA₂γ; cPLA₂γ; Group VIB PLA₂; Group IVC PLA₂; Endoplasmic reticulum

Phospholipase A₂ (PLA₂) enzymes catalyze the hydrolysis of a fatty acid from the *sn*-2 position of glycerophospholipids generating biologically active free fatty acids and lysophospholipids. Numerous members of the PLA₂ family have been identified and can be classified according to their nucleotide sequences into 14 groups designated as I–XIV [1]. The Ca²⁺-independent PLA₂ (iPLA₂) family members are iPLA₂γ (group VIB), cPLA₂γ (group IVC), and iPLA₂β (group VIA). iPLA₂γ, cPLA₂γ, and splice variants of human and rat iPLA₂β that contain exon 9 are membrane-associated [2–9]. iPLA₂γ has been cloned and overexpressed in COS-7 [2] and Sf-9 [3] cells, and associates with crude membrane fractions in both models. Yang et al. [4] reported that iPLA₂γ is located in rat liver peroxisomal

membranes. cPLA₂γ overexpression in HEK293, Sf-9, and CHO cells revealed perinuclear (endoplasmic reticulum and Golgi) membrane localization in each cell type [5–8]. One of the several splice variants of iPLA₂β was detected in crude membrane preparations of COS-7 cells after transfection and in rat vascular smooth muscle cells [9]. While these studies demonstrate that iPLA₂ can be membrane associated, the identity of specific iPLA₂ in specific membrane locations has not been fully elucidated.

Endoplasmic reticulum-associated iPLA₂ (ER-iPLA₂) activity has been described in the heart [10,11], arteriolar endothelial cells [12], and kidney [13]. We recently demonstrated that rabbit renal proximal tubular cells (RPTC) contain an ER-iPLA₂ that is inhibited by low micromolar concentrations of bromoenol lactone (BEL) [13]. Inhibition of iPLA₂ in RPTC with BEL potentiated oxidant-induced lipid peroxidation and necrotic renal cell death, but had no effect on non-oxidant-induced necrosis [13].

* Corresponding author. Fax: +1 843 792 2620.

E-mail address: schnell@musc.edu (R.G. Schnellmann).

Further, doxorubicin-induced cardiomyocyte death, which is at least partially due to lipid peroxidation, is enhanced by inhibition of membrane-associated iPLA₂ activity with BEL [14]. Based on these studies, we suggested that ER-iPLA₂ protects renal and heart cells from oxidant toxicity by inhibiting lipid peroxidation.

To further study the role of ER-iPLA₂ in oxidant-induced injury, it is necessary to determine the PLA₂ isoform(s) responsible for this activity. One method to discriminate between PLA₂ isoforms is the use of different PLA₂ inhibitors, since each enzyme has a distinct inhibition profile. The enzymatic activity of cPLA₂γ is efficiently inhibited by methyl arachidonyl fluorophosphonate (MAFP), but not the iPLA₂-specific inhibitor, bromoenol lactone (BEL), with IC₅₀ values of <1 and >30 μM, respectively [7]. iPLA₂γ and iPLA₂β, unlike cPLA₂γ, are inhibited by BEL (IC₅₀ values, 3 and <1 μM, respectively [3,15]). Cytosolic iPLA₂β is inhibited by MAFP with an IC₅₀ of approximately 1 μM [16]. ER-iPLA₂ activity in the kidney and heart is sensitive to BEL, but insensitive to MAFP [11,13], suggesting that ER-iPLA₂ activity is not cPLA₂γ or cytosolic iPLA₂β. Recently, Jenkins et al. [17] described enantioselective inhibition of iPLA₂β and iPLA₂γ by (*S*)-BEL and (*R*)-BEL, respectively. In a follow-up study, siRNA knock down of iPLA₂γ and iPLA₂β confirmed the effects of (*R*)- and (*S*)-BEL on iPLA₂γ- and iPLA₂β-mediated effects in 3T3-L1 preadipocytes [18].

Materials and methods

Materials. Female New Zealand White rabbits (1.5–2.0 kg) were purchased from Myrtle's Rabbitry (Thompson Station, TN). Male Sprague–Dawley rats (300–350 g) were purchased from Harlan (Indianapolis, IN). All other chemicals and materials were obtained from Sigma Chemical (St. Louis, MO) or reported previously [11–14,19].

Isolation of rabbit and rat tissue microsomes. Rabbits were euthanized by intravenous injection of 75 mg/kg pentobarbital sodium and rats were euthanized by intraperitoneal injection of sodium pentobarbital at 1 mg/kg. Rabbit and rat kidney cortex, heart and brain tissues were collected and placed on ice in either iPLA₂ activity buffer containing (mM): sucrose 250, KCl 10, imidazole 10, EDTA 5, and dithiothreitol 2 with 10% glycerol (pH 7.8), or iPLA₂ immunoblot buffer (activity buffer minus glycerol plus Sigma protease inhibitor cocktail, Catalog # P-8340). Cardiomyocytes were isolated from adult rabbits of either sex weighing 2–3 kg as described previously [19]. Microsomes were isolated by differential centrifugation as previously described [19,20].

Culture of Caki-1, A172, and HEK293 cell lines. The human cell lines Caki-1 (kidney carcinoma), A172 (glioblastoma), and HEK293 were purchased from ATCC (Manassas, VA). Caki-1 and A172 cells were grown under conditions recommended by ATCC. HEK293 cells were grown in DMEM (Mediatech, Herndon, VA) supplemented with 10% heat-inactivated FBS (Invitrogen, Carlsbad, CA), and 100 U/ml penicillin and 100 μg/ml streptomycin (ATCC). RNA and microsomes were all isolated from cells that were 80% confluent and at least 24 h after passage.

Isolation of rabbit RPTC, culture conditions, and inhibitor treatment. Rabbit RPTC were isolated using the iron oxide perfusion method and grown in 35-mm tissue culture dishes under improved conditions as

previously described [21,22]. Confluent monolayers were treated with (*R*)- or (*S*)-BEL or acetonitrile control for 30 min, and then microsomes were harvested as described previously [21] for activity assays.

Isolation of (*R*)- and (*S*)-enantiomers of BEL. (*R*)- and (*S*)-enantiomers of BEL were isolated from racemic BEL (Calbiochem) using a chirex 3,5-dinitrobenzoyl-(*R*)-phenylglycine chiral HPLC column (Phenomenex, Torrance, CA) using previously published methods [17]. The column was equilibrated with hexane/dichloroethane/ethanol (150:15:1) and the optical enantiomers were eluted isocratically at 2 ml/min. Elution of (*R*)- and (*S*)-BEL was monitored by UV absorbance at 280 nm. Under these conditions the retention times (*R*_t) for (*R*)- and (*S*)-BEL differ by almost 1 min with the *R*_t for (*S*)-BEL being 11.1 and 12.2 min for (*R*)-BEL [17]. Peaks corresponding to these *R*_t were collected, dried under N₂, and stored at –20 °C. The concentration of each enantiomer was determined spectrophotometrically based on its UV absorbance ($\epsilon = 6130 \text{ cm}^{-1} \text{ M}^{-1}$ in acetonitrile [17]).

Immunoblotting and iPLA₂γ antibody. We contracted Sigma-Genosys (The Woodlands, TX) to generate the anti-rabbit iPLA₂γ antibody. Briefly, a peptide corresponding to the internal sequence, CEELYRKLGSDFISQ, was conjugated to keyhole limpet hemocyanin and injected into two hens. Resultant antisera were used as the primary antibody. Equal amounts of ER protein were separated by SDS-PAGE and transferred to PVDF membranes. Membranes were incubated with the iPLA₂γ antisera at a dilution of 1:1000 and then with the goat-anti-chicken horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Bound antibodies were visualized by chemiluminescence detection on a ChemiImager 5500 imager (Alpha Innotech, San Leandro, CA).

Reverse-transcriptase-polymerase chain reaction. RNA was isolated using Trizol (Gibco-BRL, Frederick, MD). RT-PCR using total RNA isolated from human cells or tissue extracts was performed using primers designed against the sequence of group VIB PLA₂ reported in Mancuso et al. [3] (sense: 5'-ATTGATGGTGGAGGAACAAGG-3', anti-sense: 5'-ATGGCCTGCCACATTTTATAC-3'). The RT step was performed at 50 °C for 30 min followed by 2 min at 92 °C to inactivate the RT. PCR was then performed with 35 cycles of 30 s at 72 °C, 90 s at 55 °C, and 30 s at 92 °C followed by a final extension step of 2 min at 72 °C. RT-PCR products were analyzed by agarose gel electrophoresis.

Cloning and determination of rabbit iPLA₂γ nucleotide sequences. Rabbit kidney iPLA₂γ clones were generated from a rabbit kidney cDNA library (Stratagene, La Jolla, CA) by PCR analysis using primers designed against the 5' and 3'-ends of human iPLA₂γ (sense: 5'-GCATACTCGAGTCACAATTTTGAA-AAGAATGGAAGTCC-3', anti-sense: 5'-CATTCTCTCCCTTTCACTGGATCCACATAGC C-3') purchased from Integrated DNA Technologies (Coralville, IL). Negative controls for PCR included the absence of polymerase or cDNA. PCR products were separated and visualized using agarose gel electrophoresis and ethidium bromide staining. PCR products were isolated using Ultrafree-DA gel extraction columns (Millipore, Bedford, MA) and directly sequenced by automated fluorescence sequencing at the University of Georgia. Once full-length rabbit kidney iPLA₂γ cDNA sequences were isolated they were cloned between *EcoRI* sites using the TOP TA Cloning Kit from Invitrogen following the manufacturer's instructions.

Rabbit myocyte total RNA was isolated using the Versagene Cell Kit (Gentra Systems, Carlsbad, CA). 5' and 3' cDNA ends were cloned into the pCR4-TOPO vector using the GeneRacer kit (Invitrogen) according to manufacturer's instructions. Sequences were determined by automated DNA sequencing at the St. Louis University, Department of Biochemistry, DNA Sequencing Facility. Oligo(dT) primed cDNA was synthesized from rabbit total RNA and used as a template for RT-PCR amplification of full-length rabbit heart iPLA₂γ. PCR conditions and oligos used were as follows: 1 cycle (94 °C, 2 min), 35 cycles (94 °C, 1 min; 55 °C, 1 min; and 72 °C, 5 min), 1 cycle (72 °C, 10 min); FOR 5'-GCCTTGCAATCCGGTAAAGAACATG-3', REV 5'-GGGAACAG CAGATGATAAGTCAGAGCTAG-3'. PCR products were cloned

into the pCR-XL-TOPO vector and transformed into TOP10 chemically competent *Escherichia coli* (Invitrogen). Five independent kanamycin resistant clones were isolated and subjected to automated sequencing. Following assembly, a consensus sequence was generated using Vector NTI Suite 9.0 (Invitrogen).

Measurement of iPLA₂ activity. PLA₂ activity was determined under linear reaction conditions in microsomes as described previously [19]. Activity was measured using synthetic (16:0, [³H]18:1) plasmalogen (100 μM) in the absence of Ca²⁺ (presence of 4 mM EGTA). For PLA₂ activity inhibition studies, rabbit, rat, and human cell microsomal samples were incubated with either a solvent control [DMSO <0.1% (v/v)], BEL, or MAFP for 5 or 10 min prior to the addition of the phospholipid substrate to initiate the reaction.

Protein determination. Protein determination was performed using the bicinchoninic acid assay method as described by Sigma.

Statistical analysis. Microsomes or cytosol isolated from rabbit or rat tissues or from one passage of human cell cultures represented one experiment ($n = 1$). The appropriate analysis of variance (ANOVA) was performed for each data set using SigmaStat statistical software. Individual means were compared using Fisher's protected least significant difference test with $P \leq 0.05$ being considered indicative of a statistically significant difference between mean values.

Results and discussion

Microsomes from rabbit and rat tissues, and human cells possess iPLA₂ activity

While Northern blot analysis of human heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas mRNA demonstrated that these tissues express the full length 3.4-kb iPLA₂γ mRNA, activity assays nor immunoblot analysis were performed to support these data [3]. ER-iPLA₂ activities in rabbit and rat tissues, and three different human cell lines were determined by the hydrolysis of (16:0, [³H]18:1) plasmalogen substrates in the absence of Ca²⁺ (presence of 4 mM EGTA). ER-iPLA₂ activity was detected in all tissues tested (Fig. 1). Rabbit heart and brain contained higher ER-iPLA₂ activity than rabbit kidney, and rat brain activity was greater than that of rat kidney or heart (Fig. 1A). The human embryonic kidney cell (HEK293) microsomes had significantly more iPLA₂ activity than that of either the glioblastoma (A172) or kidney carcinoma (Caki-1) microsomes (Fig. 1B). Importantly, all tissues tested displayed ER-iPLA₂ activity. The significance of the differences in activity among tissues and species, and differences between normal and cancer cells has not been investigated and is beyond the scope of this study.

Identification of iPLA₂γ mRNA in rabbit, rat, and human tissues

The above data indicated that rabbit and rat tissues and human cell lines have ER-iPLA₂ activity. However, these data do not indicate what specific iPLA₂ isoforms are expressed in these tissues. RT-PCR using total RNA isolated from rabbit tissues and primers designed against




Fig. 1. Microsomal iPLA₂ activity in rabbit and rat tissues, and human cells. Microsomes were isolated from rabbits and rats and from human cells, and iPLA₂ activity was measured using (16:0, [³H]18:1) plasmalogen (100 μM) in the presence of 4 mM EGTA. (A) Microsomal iPLA₂ activity in rabbit and rat tissues. (B) Microsomal iPLA₂ activity in human cells. Values are means ± SEM of at least three separate experiments. Means with different subscripts within groups are significantly different from each other, $P < 0.05$.

the human iPLA₂γ sequence demonstrated the expression of a 475 bp cDNA product in kidney and heart (Fig. 2A). We consistently detected a faint band using RNA from rabbit brain. The 475 bp product also was detected in rat kidney, heart, and brain (Fig. 2B). The presence of two bands raises the possibility that splice variants of iPLA₂γ are transcribed in rat. Each of the three human cell lines also expressed iPLA₂γ (Fig. 2C). In conjunction with the data presented in Fig. 1, the RT-PCR results suggest that ER-iPLA₂ activity in each tissue tested is mediated by iPLA₂γ.

Rabbit iPLA₂γ shares 88% homology with human iPLA₂γ

Using the iPLA₂γ cDNA generated from total rabbit cardiomyocyte RNA (GenBank Accession No. AY738591) the amino acid sequence was determined. A comparison of the rabbit heart iPLA₂γ and the human iPLA₂γ (GenBank Accession No. NM015723) amino acid sequence is presented in Fig. 3. The conserved




Fig. 2. Presence of iPLA₂γ in rabbit and rat tissues, and human cells. Total RNA was isolated from rabbit and rat tissues, or human cell lines, and subjected to RT-PCR. Expression of iPLA₂γ cDNA products in reactions performed using total RNA isolated from: (A) rabbit tissues, (B) rat tissues, and (C) human cell lines. Controls lacked RT (–RT). Results are typical of at least three separate RNA isolations from three separate rabbits or rats, or separate passages of human cells.

Rabbit:	1	MSINLTIDICIVYLSNARMLC	GKHSKQLHLUCSPNHCWKIRHVS	LQRLHPHKVRC	KWT	60
Human:	1	MSINLTVDIYIYLSNARSVC	GKQRSKQLYFLFSPKHYWRISH	ISLQRGFHTNI	IRCKWT	60
Rabbit:	61	KSETHSCSHYYS	PSMNLNIGILK	ST	SAPKGLTKVS	IRMSR
Human:	61	KSEAHSCSHCYSP	SMNLNIGILK	ST	SAPKGLTKVNI	CHSR
Rabbit:	121	EMISRLAQKPS	SRILRKUSD	SGWLKQE	S	IKQAIRS
Human:	121	EMISRLAQKPS	SRILRKUSD	SGWLKQKNI	KAIRS	LKKYSDK
Rabbit:	181	EDDIGKQSLFHYT	GNITTKFGES	FYFLS	MNINSYFKRAEKMS	QDKENSHFQ
Human:	181	EEDIGKRSLFHYT	SSITTKFGDS	FYFLS	MNINSYFKRKEKMS	QKENEHFRDKSELEDK
Rabbit:	241	VEEGKSSSLDP	GILTSQADKP	DPKSSAGTMDKATSP	SGTPESLP	ISTKQSI
Human:	241	VEEGKLSPDP	GIL---	AYKPGSES	-VHTVDKPTSP	SAIPDVL
Rabbit:	301	GVQALVG	GYIGGLVPK	KYDSKSQAEE	QEEP	AKSEP
Human:	297	GVQALVG	GYIGGLVPK	KYDSKSQSEE	QEEP	AKTDQ
Rabbit:	361	VSIDNRTRALV	QALRRTADPKLC	ITRVEELTFHLE	FPEGKGV	AVKERI
Human:	357	VSIDNRTRALV	QALRRTADPKLC	ITRVEELTFHLE	FPEGKGV	AVKERI
Rabbit:	421	DETLQA	AVREILALIGY	DPVKGRG	IRILT	IDGGGT
Human:	417	DETLQA	AVREILALIGY	DPVKGRG	IRILS	IDGGGT
Rabbit:	481	DYIGVSTGAILA	FMLGLFHL	PLDECEEL	YRKLGSD	IFSQWV
Human:	477	DYIGVSTGAILA	FMLGLFHL	PLDECEEL	YRKLGSD	VFSQWV
Rabbit:	541	WEKILKERMGS	SALMIETARNP	MCPKVA	AUST	IUNRG
Human:	537	WENILKDRMG	SALMIETARNP	TCPKVA	AUST	IUNRG
Rabbit:	601	CQYKHUQ	AIASSAAPGYFAE	YALGNDL	NQDGG	LLNMP
Human:	597	CQYKHUQ	AIASSAAPGYFAE	YALGNDL	NQDGG	LLNMP
Rabbit:	661	SLGTGRYES	DVRNNTYTS	SLKTKLSNV	INSATDTEE	VHIMLD
Human:	657	SLGTGRYES	DVRNNTYTS	SLKTKLSNV	INSATDTEE	VHIMLD
Rabbit:	721	IPLDES	RNEKLDQLQ	LEGSKY	IERNEHKMKVAKIL	SQEKTTL
Human:	717	IPLDES	RNEKLDQLQ	LEGSKY	IERNEHKMKVAKIL	SQEKTTL
Rabbit:	781	PFFSKL				786
Human:	777	PFFSKL				782

Fig. 3. Comparison of rabbit and human iPLA₂γ amino acid sequences. NCBI Blast of the rabbit heart amino acid sequence (GenBank Accession No. AY738591) revealed 88% identity between rabbit heart and human (GenBank Accession No. NM015723) iPLA₂γ sequences. The lipase site is boxed. The rabbit amino acid sequence used to develop the iPLA₂γ antibody is underlined.

lipase site is boxed and the rabbit sequence used to develop a rabbit iPLA₂γ anti-peptide antibody is underlined. The rabbit heart and rabbit kidney (GenBank Accession No. AY739721) iPLA₂γ amino acid sequences display 88% and 80% homology with the human iPLA₂γ sequence, respectively. The regions surrounding and including residues involved in the catalytic activity of human iPLA₂γ (Ser-483, Asp-627, and Gly-Gly-Xaa-Arg-450–453 [23]) share 100% homol-

ogy, suggesting that rabbit and human iPLA₂γ possess similar lipase activity (Fig. 3).

iPLA₂γ protein is expressed in rabbit microsomes

Using the rabbit iPLA₂γ antibody, immunoreactive proteins of approximately 88 kDa were detected in microsomal fractions of rabbit kidney and heart (Fig. 4). Similar to RT-PCR results, a faint band of similar size was




Fig. 4. Immunoblot analysis of iPLA₂γ expression in rabbit tissues. Microsomes were isolated from rabbit kidney cortex (K), heart (H) or brain (B), separated by SDS-PAGE, and transferred to a PVDF membrane, and iPLA₂ expression was determined using a polyclonal anti-peptide antibody to rabbit iPLA₂γ. Each lane contained 60 μg. Blot is representative of at least three separate experiments.

routinely detected in rabbit brain microsomes. The rabbit iPLA₂γ antibody did not detect a similar sized protein in the rat or human tissues (data not shown). This is probably due to differences in the amino acid sequence between species. Based on the nucleotide sequence analysis of Mancuso et al. [3], iPLA₂γ contains four possible translation initiation codons, which correspond to protein products of 88, 77, 74, and 63 kDa. The rabbit microsomal iPLA₂γ is approximately 88 kDa, which is the long isoform of iPLA₂γ. In contrast, rat liver cells express the 63 kDa isoform of iPLA₂γ [4]. Tissue- and/or species-specific promoters responsible for expression of different sized isoforms in the rat liver, rabbit kidney and heart, are currently under study. While similar sized immunoreactive proteins have been detected in these tissues with an iPLA₂β antibody [11,13], the data presented in Fig. 4 and inhibition studies presented below demonstrate that the observed ER-iPLA₂ activity is due to iPLA₂γ in rabbit kidney and heart.

Inhibition with BEL and MAFP demonstrates differential expression of iPLA₂ isoforms across species and tissues

As discussed above, each iPLA₂ has a distinct inhibition profile. BEL inhibits iPLA₂γ and iPLA₂β but not cPLA₂γ [3,15,7]. MAFP inhibits cPLA₂γ [7] and cytosolic iPLA₂β [16], but the effects of MAFP on iPLA₂γ and membrane-associated iPLA₂β activity are not known. Rabbit kidney and heart microsomal iPLA₂ activity was significantly inhibited by BEL but not by MAFP (Fig. 5). Similar results have been previously reported [11,13]. Rat kidney microsomal iPLA₂ activity also was inhibited by BEL but not by MAFP (Fig. 5). In contrast, rabbit brain microsomal iPLA₂ activity was insensitive to BEL and sensitive to MAFP. iPLA₂ activity in rat heart and brain microsomes was significantly inhibited by both BEL and MAFP. These data illustrate the differential expression of ER-iPLA₂ isoforms across species and tissues, and suggest that rabbit




Fig. 5. Differential effect of racemic BEL and MAFP on ER-iPLA₂ activity in rabbit and rat tissues. Microsomes harvested from rabbits and rats were pretreated either with solvent control (DMSO), BEL or MAFP for 5 min, and iPLA₂ activity was measured using (16:0, [³H]18:1) plasmenylcholine (100 μM) in the presence of 4 mM EGTA. Values are means ± SEM of at least three separate experiments. Means with different subscripts within each group are significantly different from each other, $P < 0.05$.

and rat kidney and rabbit heart microsomes possess iPLA₂γ and not cPLA₂γ. Further, we suggest that rabbit brain ER-iPLA₂ activity is mediated by cPLA₂γ alone. Finally, rat heart and brain may contain iPLA₂β, iPLA₂γ, and/or cPLA₂γ. Additional studies are required to determine which isoforms are present and active in these tissues.

iPLA₂γ is responsible for microsomal iPLA₂ activity in rabbit kidney and heart and HEK293 cells

(R)- and (S)-BEL were used to confirm that iPLA₂γ is responsible for the observed activity in rabbit kidney and heart, and HEK293 cells. Primary cultures of rabbit RPTC were treated with solvent control or increasing concentrations of (R)-BEL or (S)-BEL prior to isolation of RPTC microsomes for iPLA₂ activity assays. Concentration dependent inhibition of RPTC microsomal iPLA₂ activity was observed with (R)-BEL, but not (S)-BEL, demonstrating that iPLA₂γ is responsible for iPLA₂ activity in RPTC microsomes (Fig. 6A). A similar dose-response to (R)-BEL was observed for iPLA₂ activity in microsomes isolated from rabbit cardiomyocytes (Fig. 6B). While (S)-BEL inhibits approximately 40% of the activity at 10 μM, this effect is significantly less than (R)-BEL and similar to previously published results with (S)-BEL and iPLA₂γ [17]. HEK293 microsomal iPLA₂ activity is sensitive to inhibition with racemic BEL (data not shown) and (R)-BEL, but not (S)-BEL (Fig. 6C). The selective inhibition of ER-iPLA₂ activity in rabbit kidney and heart and HEK293 cells by (R)-BEL and not (S)-BEL demonstrates that iPLA₂γ is responsible for observed activity in these cells.




Fig. 6. Differential effect of *R* and *S* enantiomers of BEL on microsomal iPLA₂ activity in RPTC, ventricular myocyte microsomes or in microsomes isolated from HEK293 cells. RPTC (A) were treated for 30 min with either (acetonitrile), *R*-BEL or *S*-BEL. Rabbit cardiomyocyte (B) and HEK293 (C) microsomes were isolated and incubated with solvent control (acetonitrile), *R*-BEL or *S*-BEL for 10 min prior to activity assays. iPLA₂ activity was measured using plasmenylcholine (16:0, [³H]18:1) or substrates in the presence of 4 mM EGTA. Values are means ± SEM of at least three separate experiments. Means with different subscripts are significantly different from each other, *P* < 0.05.

PLA₂ enzymes have been hypothesized to play a part in the repair of oxidized membranes [24]. In support of the hypothesis, glutathione peroxidase can effectively detoxify free fatty acids that are peroxidized, but only after they have been released from phospholipids by PLA₂ [25,26]. Further, in vitro studies have demonstrated that PLA₂ preferentially hydrolyze oxidized fatty acids from membranes [27,28]. The lysophospholipids generated by PLA₂ action can participate in the Lands cycle [29] and be reacylated to maintain membrane integrity. Thus, evidence exists that supports the hypothesis ER-iPLA₂ is involved in the protection of the ER membrane from lipid peroxidation induced by oxidative stress.

We have demonstrated ER-iPLA₂ activity across species and tissues, and detected the presence and activity of iPLA₂γ in microsomes of rabbit kidney and heart, rat kidney, and HEK293 cells. Based on RT-PCR and inhibition assays iPLA₂γ is also likely expressed in rat heart and brain along with other isoforms. In conjunction with our previous findings that demonstrate inhibition of microsomal iPLA₂ prior to oxidant treatment potentiates lipid peroxidation and cell death, these data suggest that iPLA₂γ is the isoform of iPLA₂ involved in protecting renal and heart cells from oxidative stress.

Acknowledgments

This work was supported by a National Research Service Award DK-10079 (to B.S.C.) and a National Institutes of Health Grant DK-62028 (to R.G.S. and J.M.).

References

- [1] D.A. Six, E.A. Dennis, The expanding superfamily of phospholipase A(2) enzymes: classification and characterization, *Biochim. Biophys. Acta* 1488 (2000) 1–19.
- [2] H. Tanaka, R. Takeya, H. Sumimoto, A novel intracellular membrane-bound calcium-independent phospholipase A(2), *Biochem. Biophys. Res. Commun.* 272 (2000) 320–326.
- [3] D.J. Mancuso, C.M. Jenkins, R.W. Gross, The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A(2), *J. Biol. Chem.* 275 (2000) 9937–9945.
- [4] J. Yang, X. Han, R.W. Gross, Identification of hepatic peroxisomal phospholipase A(2) and characterization of arachidonic acid-containing choline glycerophospholipids in hepatic peroxisomes, *FEBS Lett.* 546 (2003) 247–250.
- [5] K.W. Underwood, C. Song, R.W. Kriz, X.J. Chang, J.L. Knopf, L.L. Lin, A novel calcium-independent phospholipase A2, cPLA2-gamma, that is prenylated and contains homology to cPLA2, *J. Biol. Chem.* 273 (1998) 21926–21932.
- [6] C.M. Jenkins, X. Han, J. Yang, D.J. Mancuso, H.F. Sims, A.J. Muslin, R.W. Gross, Purification of recombinant human cPLA2 gamma and identification of C-terminal farnesylation, proteolytic processing, and carboxymethylation by MALDI-TOF-TOF analysis, *Biochemistry* 42 (2003) 11798–11807.

- [7] A. Stewart, M. Ghosh, D.M. Spencer, C.C. Leslie, Enzymatic properties of human cytosolic phospholipase A(2) gamma, *J. Biol. Chem.* 277 (2002) 29526–29536.
- [8] K. Asai, T. Hirabayashi, T. Houjou, N. Uozumi, R. Taguchi, T. Shimizu, Human group IVC phospholipase A2 (cPLA2gamma). Roles in the membrane remodeling and activation induced by oxidative stress, *J. Biol. Chem.* 278 (2003) 8809–8814.
- [9] P.K. Larsson Forsell, B.P. Kennedy, H.E. Claesson, The human calcium-independent phospholipase A2 gene multiple enzymes with distinct properties from a single gene, *Eur. J. Biochem.* 262 (1999) 575–585.
- [10] S.L. Hazen, D.A. Ford, R.W. Gross, Activation of a membrane-associated phospholipase A2 during rabbit myocardial ischemia which is highly selective for plasmalogen substrate, *J. Biol. Chem.* 266 (1991) 5629–5633.
- [11] J. McHowat, M.H. Creer, Calcium-independent phospholipase A2 in isolated rabbit ventricular myocytes, *Lipids* 33 (1998) 1203–1212.
- [12] M.H. Creer, J. McHowat, Selective hydrolysis of plasmalogens in endothelial cells following thrombin stimulation, *Am. J. Physiol.* 275 (1998) C1498–1507.
- [13] B.S. Cummings, J. McHowat, R.G. Schnellmann, Role of an endoplasmic reticulum Ca(2+)-independent phospholipase A(2) in oxidant-induced renal cell death, *Am. J. Physiol. Renal Physiol.* 283 (2002) F492–498.
- [14] J. McHowat, L.M. Swift, A. Arutunyan, N. Sarvazyan, Clinical concentrations of doxorubicin inhibit activity of myocardial membrane-associated, calcium-independent phospholipase A(2), *Cancer Res.* 61 (2001) 4024–4029.
- [15] S.L. Hazen, L.A. Zupan, R.H. Weiss, D.P. Getman, R.W. Gross, Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A2. Mechanism-based discrimination between calcium-dependent and -independent phospholipases A2, *J. Biol. Chem.* 266 (1991) 7227–7232.
- [16] Y.C. Lio, L.J. Reynolds, J. Balsinde, E.A. Dennis, Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate, *Biochim. Biophys. Acta* 1302 (1996) 55–60.
- [17] C.M. Jenkins, X. Han, D.J. Mancuso, R.W. Gross, Identification of calcium-independent phospholipase A2 (iPLA2) beta, and not iPLA2gamma, as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantio-selective mechanism-based discrimination of mammalian iPLA2s, *J. Biol. Chem.* 277 (2002) 32807–32814.
- [18] X. Su, D.J. Mancuso, P.E. Bickel, C.M. Jenkins, R.W. Gross, Small interfering RNA knockdown of calcium-independent phospholipases A2 beta or gamma inhibits the hormone-induced differentiation of 3T3-L1 preadipocytes, *J. Biol. Chem.* 279 (2004) 21740–21748.
- [19] J. McHowat, M.H. Creer, Lysophosphatidylcholine accumulation in cardiomyocytes requires thrombin activation of Ca²⁺-independent PLA2, *Am. J. Physiol.* 272 (1997) H1972–1980.
- [20] R.G. Schnellmann, T.J. Cross, E.A. Lock, Pentachlorobutadienyl-L-cysteine uncouples oxidative phosphorylation by dissipating the proton gradient, *Toxicol. Appl. Pharmacol.* 100 (1989) 498–505.
- [21] G. Nowak, R.G. Schnellmann, Improved culture conditions stimulate gluconeogenesis in primary cultures of renal proximal tubule cells, *Am. J. Physiol.* 268 (1995) C1053–1061.
- [22] G. Nowak, R.G. Schnellmann, L-Ascorbic acid regulates growth and metabolism of renal cells: improvements in cell culture, *Am. J. Physiol.* 271 (1996) C2072–2080.
- [23] H. Tanaka, R. Minakami, H. Kanaya, H. Sumimoto, Catalytic residues of group VIB calcium-independent phospholipase A2 (iPLA2gamma), *Biochem. Biophys. Res. Commun.* 320 (2004) 1284–1290.
- [24] F.J.G.M. van Kuijk, A. Sevanian, G.J. Handelman, E.A. Dratz, A new role for phospholipase A2: protection of membranes from lipid peroxidation damage, *Trends Biochem. Sci.* 12 (1987) 31–34.
- [25] A. Sevanian, S.F. Muakkassah-Kelly, S. Montestruque, The influence of phospholipase A2 and glutathione peroxidase on the elimination of membrane lipid peroxides, *Arch. Biochem. Biophys.* 223 (1983) 441–452.
- [26] F.J. van Kuijk, G.J. Handelman, E.A. Dratz, Consecutive action of phospholipase A2 and glutathione peroxidase is required for reduction of phospholipid hydroperoxides and provides a convenient method to determine peroxide values in membranes, *J. Free Radic. Biol. Med.* 1 (1985) 421–427.
- [27] M.G. Salgo, F.P. Corongiu, A. Sevanian, Peroxidation and phospholipase A2 hydrolytic susceptibility of liposomes consisting of mixed species of phosphatidylcholine and phosphatidylethanolamine, *Biochim. Biophys. Acta* 1127 (1992) 131–140.
- [28] A. Sevanian, E. Kim, Phospholipase A2 dependent release of fatty acids from peroxidized membranes, *J. Free Radic. Biol. Med.* 1 (1985) 263–271.
- [29] W.E. Lands, Lipid Metabolism, *Annu. Rev. Biochem.* 34 (1965) 313–346.